Biogen Stock Forecast, Price & News

30 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 13 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Biogen stock.
View analyst ratings for Biogen or view top-rated stocks.

Wall Street analysts have given Biogen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Biogen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Biogen saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 1,920,000 shares, a decrease of 44.8% from the June 15th total of 3,480,000 shares. Based on an average trading volume of 1,910,000 shares, the days-to-cover ratio is currently 1.0 days. Approximately 1.3% of the shares of the company are short sold.
View Biogen's Short Interest.

Biogen is scheduled to release its next quarterly earnings announcement on Wednesday, October 20th 2021.
View our earnings forecast for Biogen.

Biogen Inc. (NASDAQ:BIIB) announced its quarterly earnings results on Wednesday, July, 21st. The biotechnology company reported $5.68 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $4.55 by $1.13. The biotechnology company earned $2.78 billion during the quarter, compared to the consensus estimate of $2.61 billion. Biogen had a net margin of 16.40% and a trailing twelve-month return on equity of 34.74%. The business's revenue for the quarter was down 24.6% compared to the same quarter last year. During the same quarter last year, the business posted $10.26 earnings per share.
View Biogen's earnings history.

Biogen's stock was trading at $294.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BIIB stock has increased by 10.6% and is now trading at $325.40.
View which stocks have been most impacted by COVID-19.

Biogen declared that its Board of Directors has initiated a stock repurchase plan on Monday, December 23rd 2019, which authorizes the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to buy shares of its stock through open market purchases. Stock buyback plans are often a sign that the company's board believes its shares are undervalued.

Biogen issued an update on its FY 2021 earnings guidance on Thursday, July, 22nd. The company provided earnings per share guidance of $17.500-$19.000 for the period, compared to the Thomson Reuters consensus estimate of $18.590. The company issued revenue guidance of $10.65 billion-$10.85 billion, compared to the consensus revenue estimate of $10.63 billion.

30 analysts have issued 1-year target prices for Biogen's shares. Their forecasts range from $244.00 to $500.00. On average, they expect Biogen's stock price to reach $385.33 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price.
View analysts' price targets for Biogen or view top-rated stocks among Wall Street analysts.

186 employees have rated Biogen CEO Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among Biogen's employees.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Halozyme Therapeutics (HALO).
View all of BIIB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), The Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and The Boeing (BA).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by a number of institutional and retail investors. Top institutional investors include Country Trust Bank (0.06%), State of Alaska Department of Revenue (0.05%), Oregon Public Employees Retirement Fund (0.04%), Traynor Capital Management Inc. (0.02%), IFM Investors Pty Ltd (0.01%) and Cardinal Capital Management (0.01%). Company insiders that own Biogen stock include Alfred Sandrock, Brian S Posner, Michel Vounatsos and Stephen A Sherwin.
View institutional ownership trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including Country Trust Bank, Oregon Public Employees Retirement Fund, Traynor Capital Management Inc., 6 Meridian, Cypress Capital Group, Welch & Forbes LLC, and Compagnie Lombard Odier SCmA. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, and Brian S Posner.
View insider buying and selling activity for Biogen or view top insider-selling stocks.

BIIB stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, IFM Investors Pty Ltd, CHICAGO TRUST Co NA, Brookstone Capital Management, Taylor Cottrill Erickson & Associates Inc., Stratos Wealth Partners LTD., Cardinal Capital Management, and New Mexico Educational Retirement Board.
View insider buying and selling activity for Biogen or or view top insider-buying stocks.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIIB stock can currently be purchased for approximately $325.40.

Biogen has a market capitalization of $48.99 billion and generates $13.44 billion in revenue each year. The biotechnology company earns $4.00 billion in net income (profit) each year or $33.70 on an earnings per share basis.

Biogen employs 9,100 workers across the globe.

The following companies are subsidiares of Biogen: AliveGen, Biogen (Argentina) SRL, Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (Denmark) Manufacturing ApS, Biogen (Denmark) New Manufacturing ApS, Biogen (RTP) Realty LLC, Biogen (Singapore) Pte Ltd, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd., Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Colombia S.A.S., Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding APS, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Hong Kong Limited, Biogen Idec Ltd., Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia SRL, Biogen Japan Ltd., Biogen Korea, Biogen Luxembourg Holding SARL, Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen Mexico Servicios S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o, Biogen Poland Sp. z.o.o, Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Ltd., Eidetica Biopharma GmbH, Fumapharm, Karyopharm Therapeutics, Nightstar Europa Limited, Nightstar Inc., Nightstar Limited, Nightstar Therapeutics, Nightstar Therapeutics Limited, Old Convergence Pharmaceuticals Ltd., Panion Ltd., Remedy Pharmaceuticals, Silver Acquisition Co. Ltd., Stromedix, Stromedix Inc., Syntonix Pharmaceuticals, Tungsten Bidco Limited, and Tysabri.

Biogen was founded in 1978.

The official website for Biogen is www.biogen.com.

Biogen is headquartered at 225 BINNEY STREET, CAMBRIDGE MA, 02142.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]